Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 9Hepatitis B 7Lymphoma, Non-Hodgkin 2Lymphoma 2Hepatitis B, Chronic 2Stomach Neoplasms 1Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Tenofovir 4peginterferon alfa-2b 2entecavir 2peginterferon alfa-2a 1ibrutinib 1durvalumab 1babao dan 1Radiofrequency Ablation 1Observation 1Nucleosides 1Methods 1Interferons 1Cholecalciferol 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hepatitis B, Chronic × entecavir × Clear all
NCT04294498 2025-03-26

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

National Taiwan University Hospital

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis B, Chronic

NCT04160897 2019-11-13

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Ruijin Hospital

Unknown
4,000 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis B, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡